Seth M. Christian

For Corporates
Insights into Healthcare M&A: Q3 2024 Trends
Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Banking
Seth M. Christian

Seth M. Christian is a Senior Managing Director at Leerink Partners, leading trading for our Alternative Equities business. He has over 20 years of buy-side experience and has leveraged his healthcare fund expertise to maximize trading opportunities for one of the top franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm, Seth was a Managing Director and Head of Trading and Capital Markets at Broadfin Capital. He had a similar role and was on the launch team at the healthcare-focused fund, March Altus Capital. Earlier in his career, Seth held trading roles at Angel Lane Principal Strategy, Catapult/Millenium Partners and Sapphire Capital.

He earned a B.A. in Economics from Tufts University.

Partner With Us

Contact Us